31 results about "Resistant infection" patented technology

The present invention provides compositions useful in treating drug-resistant microorganisms and cells, as well as related methods of identifying and using such compositions. In addition, the present invention includes compositions useful in enhancing the sensitivity of both drug-resistant and drug-sensitive microorganisms and cells to microbicidal and cytotoxic agents, including antibiotics and chemotherapeutic drugs. Methods of identifying these compositions, as well as methods of using these agents in treating both drug-resistant and drug-sensitive diseases and conditions are further provided.

The present invention relates to compounds, compositions and methods for treating bacterial infections. Embodiments of the present invention include antibiotics and β-lactamase inhibitors to treat resistant infections.

A system and method for treating bacterial cells with an electrochemical process, alone or in combination with antibiotics. Weak electric currents are used to effectively eliminate bacterial cells. The method may be adapted for novel therapies of chronic infections and strategies to control persistent biofouling. The system has broad spectrum applications in treating chronic and drug resistant infections, such as those caused by Pseudomonas aeruginosa, Mycobacterium tuberculosis and methicillin resistant Staphylococcus aureus, and may also be used for decontamination of medical devices.

The invention relates to the technical field of polypeptide drugs in biochemistry, in particular to a polypeptide and application thereof. An unnatural amino acid is introduced according to an antimicrobial peptide Cbf-14 to obtain the polypeptide Cbf-14-2 having the high inhibiting activity on drug-resistant bacteria. An amino acid sequence of the antibacterial polypeptide is shown as SEQ ID: NO:1. An in-vitro antibacterial activity research shows that the polypeptide Cbf-14-2 has a more remarkable killing effect on clinic drug-resistant bacteria compared with a parent peptide Cbf-14. An in-vivo bacteremia model research shows that the polypeptide Cbf-14-2 can remarkably improve the survival rate of a rat suffering from bacteremia, the weight of the rat suffering from the bacteremia is protected, the bacterium concentration of the polypeptide in blood is reduced, and meanwhile the polypeptide has the very good treating effect on lung tissue infection inflammation caused by drug-resistant strains. The polypeptide Cbf-14-2 has very small toxicity to mammalian cells.

The invention discloses application of paeoniflorin in inhibition of growth of carbapenem-resistant klebsiella pneumoniae. According to the fact that paeoniflorin has a good in-vitro killing effect on human klebsiella pneumoniae capable of resisting imipenem and meropenem, growth of carbapenem-resistant klebsiella pneumoniae can be inhibited, the minimum bactericidal concentration is 2 mg/mL, and the minimum bacteriostatic concentration is 1.15 mg/mL. The invention provides an inhibitory effect of paeoniflorin on carbapenem-resistant klebsiella pneumoniae. According to the invention, the problem of drug-resistant infection of carbapenem-resistant klebsiella pneumoniae can be effectively relieved or solved, the mortality is reduced, a new idea is provided for inhibiting the human carbapenem-resistant klebsiella pneumoniae, and the method has important practical significance.

A ready-for-use polymer cement spacer device for the replacement of a permanent joint prosthesis during a two-stage replacement, includes a shank includes for attachment for placing to the supporting bone and a head in the joint region. The spacer device includes two complementary members incorporating rigid members for assembly between them, the first member being loaded with a first active substance and the second member being loaded with a second active substance. The first and second active substances are preferably antibiotics, selected from gentamycin, trobamycin, vancomycin, erythromycin, fucidin, tetracycline or other suitable antibiotics. The temporary joint implant maintains a suitable space for the time necessary for the operation of replacing a permanent prosthesis to prevent tissues from occupying the space released by removal of the permanent prosthesis and ensures effective treatment of resistant infections by local treatment of the joint area through at least two different active substances.

The invention discloses application of agastache rugosus volatile oil to suppression of growth of drug-resistant escherichia coli. A single chemical component, i.e. pulegone, is obtained from an agastache rugosus volatile oil to achieve a better in vitro suppression effect on the growth of human-derived drug-resistant escherichia coli, i.e. human-derived ESBLs-producing escherichia coli. The application has the beneficial effects that the first research on the effect of the agastache rugosus volatile oil on the drug-resistant escherichia coli finds that the growth of the drug-resistant escherichia coli can be suppressed; a main component serving as a drug-resistant suppressing agent is screened from the agastache rugosus volatile oil and then researched; data show that the main monomer component, i.e. the pulegone, of the agastache rugosus volatile oil can suppress the growth of the ESBLs-producing escherichia coli and affect the formation of a biofilm so as to relieve or avoid the drug-resistant infection of the escherichia coli and reduce the fatality rate; a new idea is brought up to solve and treat the human-derived ESBLs-producing escherichia coli; and the application has a great research significance.

The present disclosure provides for methods and compositions for the treatment and prevention of antibiotic-resistant infections or pathogen colonization in critically ill patients in the intensive care unit (ICU) or in other populations at high risk for such infections.

The present invention relates to the composition and method of preparing an immunogen designated as I-spga consisting of a complex antigen prepared from 18 to 26 species of pathogenic microorganisms isolated from patients, inactivated with binary ethyleneamine (BEI) and formalin, diluted in a SPGA immunopotentiator mixed with QS-21 adjuvant. By inoculating the hens with the I-spga immunogen, hyperimmune eggs (Immunospga) are obtained which contain immunologically active proteins specific to the 18-26 antigens used for immunization. The immune response of the hens is specific to the used antigens by amplification of the antigenic signal by the SPGA immunopotentiator and due to a special immunization program that allows the immune system to act complex and intense: The I-spga complex antigen contains 18-26 microorganisms isolated from patients, bacterial bodies, components from bodies obtained by ultrasonography, cilia, exotoxins, endotoxins, spores, viruses, fungi or yeasts. This pathogenic material is inactivated with BEI and formalin. The I-spga antigen is of three types. The standard I-spga antigen is composed of 18 to 24 antibiotic-resistant bacterial species isolated from patients in Romania. The specific I-spga complex antigen is composed of the I-spga complex antigen containing a mixture of 7-9 strains from a single species of bacteria, fungi or yeasts isolated from patients in Romania mixed with SPGA and QS-21, used for inoculation of hens previously immunized with standard I-spga antigen. The personalized I-spga antigen is composed of patient-derived pathological material containing cellular debris and pathogenic germs inactivated with BEI and formalin and mixed with SPGA and QS-21 and is used to immunize hens previously immunized with the standard I-spga antigen. This now patented technology encompasses a new generation of biological products in which the immune response of the hens to different groups of parenterally inoculated antigens at different time intervals is overlapping. Chicken response is uniform and additional administration of immunogens and SPGA as an immunopotentiator amplifies the antigenic signal and immune response. The I-spga immunogen as well as the immune response contain two markers, G and A, which identify the I-spga antigen used for immunization against the antigens used to produce the Imunoinstant group bio-preparations or similar products. The I-spga immunogen is used to immunize the hens for obtaining immunologically active proteins that can be used to treat immune deficiencies, psoriasis, epidermolysis bullosa, other dermatitises, nosocomial infections, antibiotic-resistant infections in the urinary system of children and grownups.

A Syringa microphylla seed extract includes the following components by weight based on a total weight of the Syringa microphylla seed extract: 0.4944-0.7142 mg/g of echinacoside, 6.624-7.617 mg/g of oleuropein, 0.4276-0.6309 mg/g of verbascoside, 3.927-4.684 mg/g of syringin, and 4.505-5.250 mg/g of forsythiaside B. A method of preparing the Syringa microphylla seed extract is disclosed. A composition for treating antibiotic-resistant infections that includes the Syringa microphylla seed extract is also disclosed.

A new route is shown for at delivery in fighting drug resistant infections. Nanotubes and antibiotics and complexed non-covalently, with no chemical bonding, but through adsorption of antibiotics onto the nanotube surface governed by sufficiently strong molecular attraction between hydrophobic systems of the two. This allows the antibiotics to be freed from the nanotubes more easily as they reach the cell membrane. When antibiotics are introduced with nanotubes in this manner, bacterial resistance is mitigated by nanotube transport potentially into the membrane of the bacteria. Nanotubes used in this way help to overcome antibiotic resistance

The invention provides a specific antibody of bacillus pyocyaneus, in particular to a bacillus pyocyaneus resistant Fab' fragment, which is extracted from the egg of laying hens immunized via bacillus pyocyaneus antigen, with high yield, better effect, stable physicochemical property, high specificity, simple preparation, better repeatability, and industrialization production support. The inventive bacillus pyocyaneus resistant Fab' fragment can significantly resist the growth of bacillus pyocyaneus, by external measurement, which can be used to prepare the drug treating bacillus pyocyaneus resistant infection.